GOLDFISCHER CARL

Director at PONIARD PHARMACEUTICALS, INC. · on record since Feb 16, 2006
Director at ZVUE CORP · on record since Aug 16, 2006
Director at ReShape Weightloss Inc. · on record since Nov 20, 2007
10% owner at ReShape Weightloss Inc. · on record since Nov 20, 2007
Director at MAP Pharmaceuticals, Inc. · on record since Oct 12, 2007
Director at CymaBay Therapeutics, Inc. · on record since Oct 11, 2013
Director at Epizyme, Inc. · on record since May 30, 2013
10% owner at Epizyme, Inc. · on record since May 30, 2013
Director at CAL-BAY INTERNATIONAL INC · on record since Jan 8, 2015
Director at Damora Therapeutics, Inc. · on record since Oct 28, 2020
Director at Enliven Therapeutics, Inc. · on record since Mar 16, 2020
10% owner at Enliven Therapeutics, Inc. · on record since Mar 16, 2020

Insider trading activity of GOLDFISCHER CARL

Transactions on record: 186; since May 20, 2004

Open-market buys: 39; $18.7M

Open-market sells: 35; $43.5M

Companies traded: 9; last filing Jun 20, 2025

Figures computed from official regulatory filings — .

Companies where GOLDFISCHER CARL has traded

Damora Therapeutics, Inc.13 tx · $100K · Jun 20, 2025
Epizyme, Inc.37 tx · $40.8M · Aug 16, 2022
Enliven Therapeutics, Inc.2 tx · Jun 3, 2022
CAL-BAY INTERNATIONAL INC32 tx · $767.9K · Feb 8, 2019
51 tx · $13M · May 31, 2017
3 tx · Jan 15, 2014
33 tx · $1.7M · Jun 10, 2011
14 tx · $75.1M · May 21, 2010
1 tx · $41.5K · Sep 5, 2007

Track record of GOLDFISCHER CARL

Statistical track record

Free account

Open-market buys: 50

Last buy: Nov 11, 2020

Win rates, median returns and the proven-insider analysis come with a free account.

Transaction history of GOLDFISCHER CARL

Co-insiders of GOLDFISCHER CARL

This page republishes public regulatory disclosures.

Company	Filed	Type	Qty	Price	Value · USD	Signals	Src
Damora Therapeutics, Inc.Listing unverified	Jun 20, 2025	AwardD (derivative)	1,440	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Jun 21, 2024	AwardD (derivative)	36,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Jun 15, 2023	AwardD (derivative)	36,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Aug 16, 2022	Other	-8,994	—	n/a (No price was disclosed in the filing)		SEC
Epizyme, Inc.Listing unverified	Aug 16, 2022	Other	-13,060	—	n/a (No price was disclosed in the filing)		SEC
Epizyme, Inc.Listing unverified	Aug 16, 2022	Other	-3,380,951	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Jun 15, 2022	AwardD (derivative)	36,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Enliven Therapeutics, Inc.Listing on record	Jun 3, 2022	AwardD (derivative)	8,500	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	May 19, 2022	AwardD (derivative)	41,006	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	May 19, 2022	Award	8,994	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 19, 2021	AwardD (derivative)	18,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Enliven Therapeutics, Inc.Listing on record	Jun 30, 2021	AwardD (derivative)	7,728	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 15, 2021	Award	8,060	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 15, 2021	AwardD (derivative)	40,559	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	May 28, 2021	AwardD (derivative)	18,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Nov 13, 2020	Buy	5,000	12.07 USD	$60.4K	conv 22First in 12mo	SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	OtherD (derivative)	-3,688	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	Other	1,020,036	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	OtherD (derivative)	-392,367	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	Other	19,432	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	AwardD (derivative)	3,688	27.11 USD	$100K		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	Other	9,587	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	OtherD (derivative)	-7,475	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 2, 2020	AwardD (derivative)	14,013	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 7, 2019	AwardD (derivative)	17,633	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC

Company	Filed	Type	Qty	Price	Value · USD	Signals	Src
Damora Therapeutics, Inc.Listing unverified	Jun 20, 2025	AwardD (derivative)	1,440	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Jun 21, 2024	AwardD (derivative)	36,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Jun 15, 2023	AwardD (derivative)	36,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Aug 16, 2022	Other	-8,994	—	n/a (No price was disclosed in the filing)		SEC
Epizyme, Inc.Listing unverified	Aug 16, 2022	Other	-13,060	—	n/a (No price was disclosed in the filing)		SEC
Epizyme, Inc.Listing unverified	Aug 16, 2022	Other	-3,380,951	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Jun 15, 2022	AwardD (derivative)	36,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Enliven Therapeutics, Inc.Listing on record	Jun 3, 2022	AwardD (derivative)	8,500	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	May 19, 2022	AwardD (derivative)	41,006	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	May 19, 2022	Award	8,994	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 19, 2021	AwardD (derivative)	18,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Enliven Therapeutics, Inc.Listing on record	Jun 30, 2021	AwardD (derivative)	7,728	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 15, 2021	Award	8,060	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 15, 2021	AwardD (derivative)	40,559	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	May 28, 2021	AwardD (derivative)	18,000	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Nov 13, 2020	Buy	5,000	12.07 USD	$60.4K	conv 22First in 12mo	SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	OtherD (derivative)	-3,688	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	Other	1,020,036	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	OtherD (derivative)	-392,367	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	Other	19,432	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	AwardD (derivative)	3,688	27.11 USD	$100K		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	Other	9,587	—	n/a (No price was disclosed in the filing)		SEC
Damora Therapeutics, Inc.Listing unverified	Nov 4, 2020	OtherD (derivative)	-7,475	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 2, 2020	AwardD (derivative)	14,013	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC
Epizyme, Inc.Listing unverified	Jun 7, 2019	AwardD (derivative)	17,633	0.00 USD	n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise))		SEC